RBOT Vicarious Surgical Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · OTC · SEC CIK 1812173 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY20.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-177.5%
ROA-115.0%
ROIC (approx.)-178.7%
Asset turnover—
Leverage & solvency
Liabilities / assets49.7%
Debt / equity0.00x
Current ratio2.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $7.14M | $7.99M | $9.05M | $9.41M | $8.46M | $10.80M | $10.92M | $9.97M |
| SG&A expense | $2.62M | $3.16M | $4.12M | $5.29M | $5.54M | $5.75M | $5.59M | $5.00M |
| Operating income | -$9.26M | -$11.50M | -$13.52M | -$15.75M | -$14.98M | -$17.75M | -$17.71M | -$16.11M |
| Pretax income | -$10.52M | -$11.06M | -$13.21M | -$15.39M | -$13.93M | -$17.09M | -$15.21M | -$17.00M |
| Net income | -$10.52M | -$11.06M | -$13.21M | -$15.39M | -$13.93M | -$17.09M | -$15.21M | -$17.00M |
| EBITDA | -$8.97M | -$11.15M | -$13.11M | -$15.38M | -$14.44M | -$17.25M | -$17.19M | -$15.59M |
| EPS (basic) | — | — | — | — | — | — | -2.59 | -0.10 |
| EPS (diluted) | — | — | — | — | — | — | -2.59 | -0.10 |
| Weighted avg. shares (diluted) | — | 5.95M | 5.94M | 5.92M | — | 5.90M | 5.87M | 5.86M |
| Balance sheet | ||||||||
| Cash & equivalents | $2.57M | $3.16M | $3.91M | $2.60M | $9.74M | $8.01M | $21.19M | $39.16M |
| Short-term investments | $7.22M | $10.25M | $20.05M | $34.76M | $39.36M | $53.80M | $52.98M | $45.90M |
| Current assets | $11.58M | $15.07M | $26.07M | $39.65M | $51.70M | $63.98M | $75.93M | $87.11M |
| PP&E, net | $1.27M | $3.48M | $3.79M | $4.11M | $4.48M | $4.82M | $5.33M | $5.89M |
| Total assets | $19.58M | $29.35M | $40.89M | $55.05M | $67.72M | $80.62M | $93.35M | $105.29M |
| Current liabilities | $3.90M | $3.18M | $5.10M | $7.86M | $7.67M | $8.60M | $7.18M | $5.08M |
| Total liabilities | $9.74M | $15.26M | $17.83M | $20.98M | $21.02M | $22.73M | $21.49M | $21.28M |
| Shareholders' equity | $9.84M | $14.09M | $23.06M | $34.08M | $46.70M | $57.88M | $71.86M | $84.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.31M | -$10.46M | -$13.53M | -$11.77M | -$11.79M | -$12.69M | -$11.02M | -$14.46M |
| Capital expenditure | — | — | $0 | $5,000 | — | — | $6,000 | $10,000 |
| Free cash flow | — | — | -$13.53M | -$11.77M | — | — | -$11.03M | -$14.47M |
| Investing cash flow | $3.02M | $9.69M | $14.82M | $4.61M | $14.45M | -$492,000 | -$6.95M | -$144,000 |
| Financing cash flow | $5.69M | $26,000 | $24,000 | $17,000 | $6,000 | $0 | $0 | $2,000 |
| Depreciation & amortization | $291,000 | $352,000 | $413,000 | $369,000 | $542,000 | $507,000 | $524,000 | $521,000 |
| Stock-based compensation | $1.10M | $2.05M | $2.20M | $2.79M | $2.81M | $2.94M | $3.07M | $3.09M |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.